The medical technology company ViaLase will reveal the 2-year data from their FLigHT clinical study as well as give additional information about their pipeline at ASCRS 2023.
ViaLase announced that they will present clinical data from their first-in-human initial study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) as well as a technology overview at The American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will be held May 5-8, 2023 in San Diego, California. The clinical-stage medical tech company is developing a noninvasive image-guided femtosecond laser for the treatment of glaucoma in the hopes of addressing unmet needs in the conventional treatment paradigm.
“We are excited to present our 2-year clinical data to the ophthalmic community and continue to share the potential value of the micron accuracy, non-invasive treatment of glaucoma performed with advanced image-guided, femtosecond laser technology,” Tibor Juhasz, PhD, founder and CEO of ViaLase, said in a press release. “The results mark an important first step in demonstrating FLigHT’s potential as a safe and effective treatment option for patients with primary open angle glaucoma. We are optimistic about the new opportunities ViaLase’s FLigHT treatment can offer to practices and patients alike.”
Presenters for ViaLase include Cathleen M. McCabe, MD; Professor Zoltan Nagy, MD; and Richard A. Lewis, MD.
Thomas W. Samuelson, MD, will also present a Marketplace Company Showcase as a part of Eyecelerator, a popular pipeline review and technology spotlight that often accompanies major meetings. Eyecelerator will take place on Thursday, May 4, 2023 from 1:00-2:30 pm PDT.